At a glance
Effects
- Appetite suppression: Raises satiety signals via enhanced serotonin and norepinephrine activity in the hypothalamus, reducing hunger and food anticipation. [1]
- Weight reduction: Clinical trials showed dose-related weight loss up to ~11% below baseline sustained for up to 18 months with continued treatment. [4]
- Thermogenesis: Stimulates efferent sympathetic activity to brown adipose tissue, modestly increasing energy expenditure. [4]
- Heart rate & blood pressure elevation: Noradrenergic activity raises blood pressure and heart rate in a clinically significant proportion of users — this is an effect, not just a side effect. [6]
SNRI-class anorexiant (NOT an AAS) — withdrawn from US/EU markets [1][2]
Parent: ~1 h; active metabolites M1 & M2: 14–16 h [5]
Oral (capsule/tablet) [5]
Withdrawn — US (Oct 2010), EU (Jan 2010); Schedule IV controlled substance (US) [2][7]
Hepatic via CYP3A4 → active metabolites M1 & M2 [5]
About Sibutramine
Every point here is drawn from public medical and harm-reduction sources. A bracketed number after a claim — like [1]— is a reference: tap it to open the exact source it's based on (numbered list at the bottom). It is not a rating or score. Educational information, not medical advice.
Product specifics
- Est. delivery
- 3–7 business days · EU tracked
Product details as stated by the vendor (claims, not independently verified). Delivery is our standard EU estimate.
What it is
Sibutramine is a centrally-acting serotonin-norepinephrine-dopamine reuptake inhibitor (SNRI-class anorexiant) originally developed as an anti-obesity medication. It is NOT an anabolic-androgenic steroid — any vendor labelling it as AAS is incorrect. It was withdrawn from US and EU markets in 2010 due to serious cardiovascular risks. [1][2]
How it works
Sibutramine inhibits the presynaptic reuptake of serotonin (by ~54%), norepinephrine (by ~73%), and to a lesser extent dopamine (by ~16%) in the central nervous system, increasing their availability in the synaptic cleft. [3] This raises satiety signals and suppresses appetite via hypothalamic pathways, while also stimulating thermogenesis through increased sympathetic nervous system activity to brown fat. [4] The parent drug itself has a short half-life (~1 hour), but it is rapidly metabolised by CYP3A4 in the liver into two pharmacologically active metabolites (M1 and M2) that carry the majority of its clinical effect and have elimination half-lives of 14–16 hours. [5]
Risks & side effects
Most important: Sibutramine was withdrawn from the US and European markets in 2010 because the SCOUT trial found a 16% higher risk of major adverse cardiovascular events — including non-fatal heart attack and stroke — in treated patients compared with placebo. [7][8] This cardiovascular risk is the single most critical danger; anyone with pre-existing heart disease, hypertension, or cardiovascular risk factors must not use this substance.
Common
Serious
Rare
- Sudden cardiac death — documented in case reports, including in patients without prior known heart disease [10]
- Acute coronary syndrome in otherwise healthy individuals [10]
- Covert exposure via adulterated herbal/weight-loss supplements (sibutramine found illegally in 27+ 'natural' products per FDA alert) [11]
Safety & harm reduction
- Any history of cardiovascular disease, heart attack, stroke, or arrhythmia [7][8]
- Uncontrolled or poorly controlled hypertension [8]
- Patients over 65 years of age (FDA added contraindication Aug 2010) [11]
- Concurrent use of MAOIs (risk of serious serotonergic/adrenergic crisis) [1]
- Concurrent use of other serotonergic drugs (SSRIs, SNRIs, triptans) due to serotonin syndrome risk [1]
- Pregnancy or breastfeeding
- Hyperthyroidism or glaucoma
- MAOIs (phenelzine, tranylcypromine, selegiline): potentially fatal serotonergic/adrenergic crisis — absolute contraindication [1]
- SSRIs / SNRIs / triptans: additive serotonin risk, serotonin syndrome [1]
- CYP3A4 inhibitors (ketoconazole, erythromycin, ritonavir): increase sibutramine and active metabolite plasma levels [5]
- CYP3A4 inducers (rifampicin, carbamazepine): reduce active metabolite levels [5]
- Clopidogrel: significantly increases sibutramine half-life and plasma exposure [12]
- Sympathomimetics / decongestants: additive blood pressure and heart rate elevation
- Sibutramine is a globally withdrawn drug — there is no approved use protocol. If encountered in supplements, stop immediately and seek medical advice [2][10]
- No anabolic or AAS-related PCT protocol applies — this is not a steroid or SERM
- If inadvertent exposure occurred, monitor blood pressure and heart rate and contact a healthcare provider
Dosage context
When sibutramine was approved, the historically reported clinical starting dose was 10 mg orally once daily, adjustable by 5 mg depending on response, with a studied range of 10–15 mg/day (SCOUT trial used 10–15 mg/day). [9][13] This is provided for harm-reduction context ONLY — sibutramine is withdrawn from regulated markets worldwide and NO safe or sanctioned dosing protocol exists today.
Sources
- 1.DrugBank — Sibutramine drug entry
- 2.Wikipedia — Sibutramine (regulatory history)
- 3.PMC — Sibutramine: central mechanisms regulating energy homeostasis
- 4.PubMed — Safety and efficacy of sibutramine (novel mechanism)
- 5.ScienceDirect — Sibutramine pharmacokinetics overview
- 6.DrugBank — Sibutramine SNRI review (Ann Pharmacother 1999)
- 7.MDedge — Sibutramine withdrawn due to CV risks (SCOUT trial)
- 8.ScienceDirect Neuroscience — Sibutramine overview (SCOUT, contraindications)
- 9.PMC — Sibutramine on Cardiovascular Outcome (NIH)
- 10.PMC — Sibutramine as a cause of sudden cardiac death
- 11.Medscape — FDA announces sibutramine market withdrawal
- 12.PubMed — Clopidogrel interaction with sibutramine pharmacokinetics
- 13.PMC — Sibutramine cardiovascular cohort study (UK)
This information is provided for educational and harm-reduction purposes only. It is not medical advice. These substances can carry serious health risks; effects and safe use vary by individual. Consult a qualified healthcare professional before use. Legal status varies by country — it is your responsibility to know your local law. We do not encourage misuse.
Other options for Sibutramine· 2 offers
Same compound from different labs/brands and pack sizes. Tap a row to switch brand — the price and buy button update instantly.
This compound comes in different forms (e.g. injectable vs oral vs topical). Cost per mg is only comparable within the same form.
| Brand | Form | Strength | Pack | Price | Per mg |
|---|---|---|---|---|---|
Generic | oral-liquid | 20 mg/ml | 100 ml | 84,90 € | €0.042/mg |
NouveauxSelected | blister-pack | 20 mg/tab | 100 tab | 129,99 € | €0.065/mg |